Clinoscope buys 40 million Neimeth shares for N312 million after 2025 sell-off

Neimeth International Pharmaceuticals has seen a major institutional shareholder, Clinoscope Services Limited, increase its stake by purchasing 40 million shares. The transaction, completed on August 4, 2026, in Lagos, cost N312 million at a rate of N7.80 per share. This brings Clinoscope's ownership to 592,975,860 shares, up from 552,975,860 prior to the purchase.

The move comes after a 48.28% year-to-date increase in the share price, from N5.80 at year-end 2025 to N8.60. This represents a significant reversal of a 2025 divestment where Clinoscope sold 515.3 million shares in two rounds. The latest acquisition represents about 7.8% of the shares sold in 2025 and signals renewed confidence in Neimeth's strategic direction and growth plans.

The acquisition coincides with Neimeth's ongoing efforts to enhance its financial position through capital restructuring and fresh fundraising. In June, shareholders approved a N30 billion capital raise during the company's 67th Annual General Meeting, increasing Neimeth's total fundraising mandate to N50 billion. The company reported a pre-tax profit of N1.49 billion for the year ended December 31, 2025, a stark contrast to the N854.43 million loss in 2024, reflecting a 274% improvement.